Evidence map›Paper›PMID 37941685›Full record

ArticleJMA journal2023

Potential Risk of Overlooking Biased Reporting of Vaccination against Novel Coronavirus Disease 2019: Lessons from Japan's Experience with the Human Papillomavirus Vaccine.

Yudai Kaneda, Mira Namba

Open access · diamondAbstract read
In one paragraph

Article in JMA journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Yudai KanedaSchool of Medicine, Hokkaido University, Hokkaido, Japan.
Mira NambaSchool of Medicine, Keio University, Tokyo, Japan.
Hokkaido University · JPKeio University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vaccination is a crucial and evidence-based measure against novel coronavirus disease 2019 (COVID-19) implemented worldwide, including in Japan, where more than 67% of the population has received more than three doses of vaccination as of February 2023. Although some common adverse reactions of the vaccine, such as fever and arm pain, have been reported, serious adverse reactions resulting in death, such as myocarditis and Guillain-Barré syndrome, are rare. However, the biased reporting of the adverse reactions of the COVID-19 vaccine in the Japanese media has recently become more frequent, which is similar to the past biased reporting on the human papillomavirus (HPV) vaccine. Previously, the media's biased reporting on the HPV vaccine caused public mistrust in vaccines, leading to a drop in vaccination rates in Japan. Thus, overlooking the sensational reporting of the media on the current COVID-19 vaccine may potentially influence people's health behavior and awareness in the long run. Actually, experts worldwide agree that the COVID-19 vaccine is safe, and the media reports are inconsistent with the observations. Thus, it is necessary to urge the media to release accurate information to prevent tragedies caused by biased reporting. Moreover, it is essential to correct misinformation in reporting, disseminate accurate information from media outlets, such as Internet news and video-sharing sites, and promote awareness among people to support the vaccination rate against COVID-19.

Indexed as

Adverse reactionCOVID-19HPV vaccineJapanVaccination

Identifiers

PMID37941685
PMCPMC10628147
OpenAlexW4387546971

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.